BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.22−0.10 (-1.37%)
Close on Nov 20, 2026Market cap $1.84BP/E –Yield –
BioCryst Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BioCryst Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $373.38M, up 2269.0% year over year. For fiscal 2025 it was $344.90M. The highest annual figure on record is $344.90M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $344.90M | – |
| FY2024 | Dec 31, 2024 | -$53.14M | – |
| FY2023 | Dec 31, 2023 | -$97.31M | – |
| FY2022 | Dec 31, 2022 | -$163.20M | – |
| FY2021 | Dec 31, 2021 | -$144.54M | – |
| FY2020 | Dec 31, 2020 | -$135.62M | – |
| FY2019 | Dec 31, 2019 | -$89.93M | – |
| FY2018 | Dec 31, 2018 | -$92.93M | – |
| FY2017 | Dec 31, 2017 | -$41.47M | – |
| FY2016 | Dec 31, 2016 | -$58.72M | – |
| FY2015 | Dec 31, 2015 | -$18.24M | – |
| FY2014 | Dec 31, 2014 | -$38.66M | – |
| FY2013 | Dec 31, 2013 | -$26.56M | – |
| FY2012 | Dec 31, 2012 | -$37.51M | – |
| FY2011 | Dec 31, 2011 | -$32.31M | – |
| FY2010 | Dec 31, 2010 | -$28.88M | – |
| FY2009 | Dec 31, 2009 | -$16.82M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $104.13M | +153.2% |
| Q1 FY2026 | Mar 31, 2026 | -$62.19M | – |
| Q4 FY2025 | Dec 31, 2025 | $291.16M | – |
| Q3 FY2025 | Sep 30, 2025 | $40.28M | +392.1% |
| Q2 FY2025 | Jun 30, 2025 | $41.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.89M | – |
| Q3 FY2024 | Sep 30, 2024 | $8.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$53.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.28M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.38M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$78.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.64M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$61.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$42.69M | – |
| Q3 FY2020 | Sep 30, 2020 | -$38.43M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.40M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.53M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.72M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.59M | – |
| Q1 FY2019 | Mar 31, 2019 | -$27.09M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$35.07M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$19.69M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.63M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.62M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.69M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.53M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.85M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.74M | – |
See a number that looks wrong?